17TH Clinical Trials on Alzheimer’s Disease (CTAD) | Oct 29- Nov 1, 2024
October 29, 2024 — Porsteinsson, M.D.
Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease; Efficacy and Safety from the LIFT-AD Trial
October 29, 2024 — Porsteinsson, M.D.
Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease; Efficacy and Safety from the LIFT-AD Trial